Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses

Virology

Volumn 446, Issue 1-2, 2013, Pages 37-48

  Vollmers, Ellen M ^a   Tattersall, Peter ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Melanoma; Oncolytic parvovirus; Virus induced cell death

Indexed keywords

ONCOLYTIC PARVOVIRUS;

ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL FATE; CELL KILLING; DNA REPLICATION; DRUG MECHANISM; DRUG TARGETING; GENE MAPPING; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PARVOVIRUS INFECTION; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSCRIPTION;

MELANOMA; ONCOLYTIC PARVOVIRUS; VIRUS-INDUCED CELL DEATH;

CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MELANOMA; ONCOLYTIC VIRUSES; PARVOVIRUS;

EID: 84884691678     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.07.013     Document Type: Article

References (59)

1. Bergeron J., Hébert B., Tijssen P. Genome organization of the Kresse strain of porcine parvovirus: identification of the allotropic determinant and comparison with those of NADL-2 and field isolates. J. Virol. 1996, 70:2508-2515.
2. Bhat R., Dempe S., Dinsart C., Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int. J. Cancer 2011, 128:908-919.
3. Bloom M.E., Berry B.D., Wei W., Perryman S., Wolfinbarger J.B. Characterization of chimeric full-length molecular clones of Aleutian mink disease parvovirus (ADV): identification of a determinant governing replication of ADV in cell culture. J. Virol 1993, 67:5976-5988.
4. Chin L., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.-P., Nickerson E., Auclair D., Li L., Place C., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
5. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006, 20:2149-2182.
6. Choi E.-Y., Newman A.E., Burger L., Pintel D. Replication of minute virus of mice DNA is critically dependent on accumulated levels of NS2. J. Virol. 2005, 79:12375-12381.
7. Cornelis J.J., Chen Y.Q., Spruyt N., Duponchel N., Cotmore S.F., Tattersall P., Rommelaere J. Susceptibility of human cells to killing by the parvoviruses H-1 and minute virus of mice correlates with viral transcription. J. Virol. 1990, 64:2537-2544.
8. Cotmore S.F., Tattersall P. Organization of nonstructural genes of the autonomous parvovirus minute virus of mice. J. Virol. 1986, 58:724-732.
9. Cotmore S.F., Tattersall P. Encapsidation of minute virus of mice DNA: aspects of the translocation mechanism revealed by the structure of partially packaged genomes. Virology 2005, 336:100-112.
10. Cotmore S.F., Tattersall P. Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of parvoviruses minute virus of mice and LuIII. J. Virol 2005, 79:2287-2300.
11. Cotmore S.F., Tattersall P. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 2007, 70:183-232.
12. Cotmore S.F., Tattersall P. Parvovirus diversity and DNA damage responses. DNA Replication. Cold Spring Harbor Perspectives in Biology 2013, 457-468. Cold Spring Harbor Laboratory Press. S.D. Bell, M. Mechali, DePamphilis (Eds.).
13. Cotmore S.F., D'Abramo A.M., Carbonell L.F., Bratton J., Tattersall P. The NS2 Polypeptide of parvovirus MVM is required for capsid assembly in murine cells. Virology 1997, 231:267-280.
14. Cotmore S.F., Hafenstein S., Tattersall P. Depletion of virion-associated divalent cations induces parvovirus minute virus of mice to eject its genome in a 3"-to-5" direction from an otherwise intact viral particle. J. Virol. 2010, 84:1945-1956.
15. D'Abramo A.M., Ali A.A., Wang F., Cotmore S.F., Tattersall P. Host range mutants of minute virus of mice with a single VP2 amino acid change require additional silent mutations that regulate NS2 accumulation. Virology 2005, 340:143-154.
16. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
17. Di Piazza M., Mader C., Geletneky K., Herrero Y., Calle M., Weber E., Schlehofer J., Deleu L., Rommelaere J. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J. Virol. 2007, 81:4186-4198.
18. Donahue J.M., Mullen J.T., Tanabe K.K. Viral oncolysis. Surg. Oncol. Clin. N. Am. 2002, 11:661-680.
19. Dupont F., Avalosse B., Karim A., Mine N., Bosseler M., Maron A., Van den Broeke A.V., Ghanem G.E., Burny A., Zeicher M. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Ther 2000, 7:790-796.
20. Dupont F. Risk assessment of the use of autonomous parvovirus-based vectors. Curr Gene Ther 2003, 3:567-582.
21. Eichwald V., Daeffler L., Klein M., Rommelaere J., Salomé N. The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. J. Virol 2002, 76:10307-10319.
22. El Bakkouri K., Servais C., Clément N., Cheong S.C., Franssen J.-D., Velu T., Brandenburger A. In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA. J Gene Med 2005, 7:189-197.
23. Farr G.A., Tattersall P. A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection. Virology 2004, 323:243-256.
24. Gardiner E.M., Tattersall P. Evidence that developmentally regulated control of gene expression by a parvoviral allotropic determinant is particle mediated. J. Virol 1988, 62:1713-1722.
25. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
26. Geletneky K., Kiprianova I., Ayache A., Koch R., Herrero Y., Calle M., Deleu L., Sommer C., Thomas N., Rommelaere J., Schlehofer J.R. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro-Oncology 2010, 12:804-814.
27. Grekova S.P., Raykov Z., Zawatzky R., Rommelaere J., Koch U. Activation of a glioma-specific immune response by oncolytic parvovirus minute virus of mice infection. Cancer Gene Ther 2012, 19:468-475.
28. Grekova S., Aprahamian M., Giese N., Schmitt S., Giese T., Falk C.S., Daeffler L., Cziepluch C., Rommelaere J., Raykov Z. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol. Ther. 2011, 10:1280-1289.
29. Gupta P.B., Kuperwasser C., Brunet J.-P., Ramaswamy S., Kuo W.-L., Gray J.W., Naber S.P., Weinberg R.A. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 2005, 37:1047-1054.
30. Hallauer C., Siegl G., Kronauer G. Parvoviruses as contaminants of permanent human cell lines. 3. Biological properties of the isolated viruses. Arch. Gesamte Virusforsch. 1972, 38:366-382.
31. Hocker T.L., Singh M.K., Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol. 2008, 128:2575-2595.
32. Lang S.I., Giese N.A., Rommelaere J., Dinsart C., Cornelis J.J. Humoral immune responses against minute virus of mice vectors. J. Gene Med. 2006, 8:1141-1150.
33. Maroto B., Valle N., Saffrich R., Almendral J.M. Nuclear export of the nonenveloped parvovirus virion is directed by an unordered protein signal exposed on the capsid surface. J. Virol. 2004, 78:10685-10694.
34. Miller C.L., Pintel D.J. Interaction between parvovirus NS2 protein and nuclear export factor Crm1 is important for viral egress from the nucleus of murine cells. J. Virol. 2002, 76:3257-3266.
35. Mincberg M., Gopas J., Tal J. Minute virus of mice (MVMp) infection and NS1 expression induce p53 independent apoptosis in transformed rat fibroblast cells. Virology 2011, 412:233-243.
36. Moehler M., Blechacz B., Weiskopf N., Zeidler M., Stremmel W., Rommelaere J., Galle P.R., Cornelis J.J. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther. 2001, 8:158-167.
37. Naeger L.K., Cater J., Pintel D.J. The small nonstructural protein (NS2) of the parvovirus minute virus of mice is required for efficient DNA replication and infectious virus production in a cell-type-specific manner. J. Virol. 1990, 64:6166-6175.
38. Naeger L.K., Salomé N., Pintel D.J. NS2 is required for efficient translation of viral mRNA in minute virus of mice-infected murine cells. J. Virol. 1993, 67:1034-1043.
39. Paglino J., Burnett E., Tattersall P. Exploring the contribution of distal P4 promoter elements to the oncoselectivity of Minute Virus of Mice. Virology 2007, 361:174-184.
40. Paglino J., Tattersall P. The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts. Virology 2011, 416:32-41.
41. Paradiso P.R. Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity. J. Virol. 1981, 39:800-807.
42. Parrish C.R., Carmichael L.E. Characterization and recombination mapping of an antigenic and host range mutation of canine parvovirus. Virology 1986, 148:121-132.
43. Prestwich R.J., Harrington K.J., Pandha H.S., Vile R.G., Melcher A.A., Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev. Anticancer Ther. 2008, 8:1581-1588.
44. Previsani N., Fontana S., Hirt B., Beard P. Growth of the parvovirus minute virus of mice MVMp3 in EL4 lymphocytes is restricted after cell entry and before viral DNA amplification: cell-specific differences in virus uncoating in vitro. J. Virol. 1997, 71:7769-7780.
45. Ran Z., Rayet B., Rommelaere J., Faisst S. Parvovirus H-1-induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis. Virus Res. 1999, 65:161-174.
46. Ravnan M.C., Matalka M.S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin. Ther. 2012, 34:1474-1486.
47. Rayet B., Lopez-Guerrero J.A., Rommelaere J., Dinsart C. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J. Virol. 1998, 72:8893-8903.
48. Raykov Z., Grekova S., Galabov A.S., Balboni G., Koch U., Aprahamian M., Rommelaere J. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol. Rep. 2007, 17:1493-1499.
49. Raykov Z., Savelyeva L., Balboni G., Giese T., Rommelaere J., Giese N.A. B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression. J. Virol. 2005, 79:3517-3524.
50. Robert C., Thomas L., Bondarenko I.,O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J.-J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
51. Rubio M.P., Guerra S., Almendral J.M. Genome replication and postencapsidation functions mapping to the nonstructural gene restrict the host range of a murine parvovirus in human cells. J. Virol. 2001, 75:11573-11582.
52. Ruiz Z., Mihaylov I.S., Cotmore S.F., Tattersall P. Recruitment of DNA replication and damage response proteins to viral replication centers during infection with NS2 mutants of minute virus of mice (MVM). Virology 2011, 410:375-384.
53. Tijssen P., Agbandje-McKenna M., Almendral J.M., Bergoin M., Flegel T.W., Hedman K., Kleinschmidt J.A., Li Y., Pintel D.J., Tattersall.P. Parvoviridae. Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses 2011, 375-395. Elsevier, San Diego. A.M.Q. King, M.J. Adams, E. Carstens, E.J. Lefkowitz (Eds.).
54. Tworkoski K., Singhal G., Szpakowski S., Zito C.I., Bacchiocchi A., Muthusamy V., Bosenberg M., Krauthammer M., Halaban R., Stern D.F. Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol. Cancer Res. 2011, 9:801-812.
55. Wetzel K., Struyf S., Van Damme J., Kayser T., Vecchi A., Sozzani S., Rommelaere J., Cornelis J.J., Dinsart C. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int. J. Cancer 2007, 120:1364-1371.
56. Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann. Oncol. 23 2012, (Suppl 8):viii15-viii21.
57. Wollmann G., Ozduman K., van den Pol A.N. Oncolytic virus therapy for glioblastoma multiforme. Cancer J. 2012, 18:69-81.
58. Yeung D.E., Brown G.W., Tam P., Russnak R.H., Wilson G., Clark-Lewis I., Astell C.R. Monoclonal antibodies to the major nonstructural nuclear protein of minute virus of mice. Virology 1991, 181:35-45.
59. Zitvogel L., Apetoh L., Ghiringhelli F., André F., Tesniere A., Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 2008, 118:1991-2001.